en
Scientific article
English

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008

Published inArchives of internal medicine, vol. 170, no. 1, p. 57-65
Publication date2010
Abstract

BACKGROUND: Adverse effects of combination antiretroviral therapy (CART) commonly result in treatment modification and poor adherence. METHODS: We investigated predictors of toxicity-related treatment modification during the first year of CART in 1318 antiretroviral-naive human immunodeficiency virus (HIV)-infected individuals from the Swiss HIV Cohort Study who began treatment between January 1, 2005, and June 30, 2008. RESULTS: The total rate of treatment modification was 41.5 (95% confidence interval [CI], 37.6-45.8) per 100 person-years. Of these, switches or discontinuations because of drug toxicity occurred at a rate of 22.4 (95% CI, 19.5-25.6) per 100 person-years. The most frequent toxic effects were gastrointestinal tract intolerance (28.9%), hypersensitivity (18.3%), central nervous system adverse events (17.3%), and hepatic events (11.5%). In the multivariate analysis, combined zidovudine and lamivudine (hazard ratio [HR], 2.71 [95% CI, 1.95-3.83]; P <.001), nevirapine (1.95 [1.01-3.81]; P =.050), comedication for an opportunistic infection (2.24 [1.19-4.21]; P =.01), advanced age (1.21 [1.03-1.40] per 10-year increase; P =.02), female sex (1.68 [1.14-2.48]; P =.009), nonwhite ethnicity (1.71 [1.18-2.47]; P =.005), higher baseline CD4 cell count (1.19 [1.10-1.28] per 100/microL increase; P <.001), and HIV-RNA of more than 5.0 log(10) copies/mL (1.47 [1.10-1.97]; P =.009) were associated with higher rates of treatment modification. Almost 90% of individuals with treatment-limiting toxic effects were switched to a new regimen, and 85% achieved virologic suppression to less than 50 copies/mL at 12 months compared with 87% of those continuing CART (P =.56). CONCLUSIONS: Drug toxicity remains a frequent reason for treatment modification; however, it does not affect treatment success. Close monitoring and management of adverse effects and drug-drug interactions are crucial for the durability of CART.

Keywords
  • AIDS-Related Opportunistic Infections/drug therapy/epidemiology
  • Adenine/administration & dosage/adverse effects/analogs & derivatives
  • Adult
  • Anti-HIV Agents/administration & dosage/ adverse effects
  • Benzoxazines/administration & dosage/adverse effects
  • Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives
  • Dideoxynucleosides/administration & dosage/adverse effects
  • Drug Therapy, Combination
  • Female
  • HIV Infections/ drug therapy/epidemiology
  • Humans
  • Lamivudine/administration & dosage/adverse effects
  • Male
  • Middle Aged
  • Nevirapine/administration & dosage/adverse effects
  • Oligopeptides/administration & dosage/adverse effects
  • Phosphonic Acids/administration & dosage/adverse effects
  • Proportional Hazards Models
  • Prospective Studies
  • Pyridines/administration & dosage/adverse effects
  • Pyrimidinones/administration & dosage/adverse effects
  • Risk Factors
  • Switzerland/epidemiology
  • Zidovudine/administration & dosage/adverse effects
Citation (ISO format)
ELZI, Luigia et al. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. In: Archives of internal medicine, 2010, vol. 170, n° 1, p. 57–65. doi: 10.1001/archinternmed.2009.432
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0003-9926
474views
0downloads

Technical informations

Creation06/21/2010 10:23:53 AM
First validation06/21/2010 10:23:53 AM
Update time03/14/2023 3:43:21 PM
Status update03/14/2023 3:43:21 PM
Last indexation02/12/2024 6:28:59 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack